We found that the probability of disease-free survival was severely reduced in patients expressing high levels of HuR and ARID1A, highlighting the clinical role of the HuR–ARID1A axis in patients with breast cancer (Supplementary Figure S2G). This evidence concerns the gene ELAVL1 and breast carcinoma.